Investors
Overview

Investors Overview

Company Profile

Altimmune is a clinical stage biopharmaceutical company focused on developing next generation peptide therapeutics for liver disease and immuno-oncology. Our pipeline includes treatments for NASH (ALT-801), chronic Hepatitis B (HepTcell™), and conjugated immunostimulants for the treatment of cancer (ALT-702).

In addition, we have two intranasal vaccine programs for Anthrax (NasoShield™) and Influenza (NasoVAX™) developed with external funding.

 

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe